These shares have consolidated recently and have attempted to breakout above the $1.65 level .Consensus Target Price remains $4.00 and rated as a BUY . A seven fold increase in dental sales Q3 over Q2 2020 we believe will drive these shares  significantly higher in the coming months .

Two Wall Street analysts have issued ratings and price targets for Milestone Scientific in the last 12 months. Their average twelve-month price target is $4.00, predicting that the stock has a possible upside of 166.67%. The high price target for MLSS is $4.00 and the low price target for MLSS is $4.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Milestone Scientific Inc. (MLSS NYSE) reported total sales of $1.2 million this week, thanks mainly to the reopening of many businesses that rely on medical and dental products. Milestone Scientific is committed to advancing the science of computer-controlled drug delivery systems that provide significant increases in efficiency and patient comfort for the medical and dental segments. Thanks to the reputation it has built up over the years, the company now sees sales of dental products going up rapidly.

The Q3 figures show potential

That is not a bad development, especially in view of the situation in which the world finds itself. Last Tuesday, the results for the third quarter of 2020 were released, just as sales of dental products started to pick up again by the day. Compared to the second quarter of this year, sales are now almost seven times higher. Earlier many dental operations were canceled or severely curtailed in that quarter, but that now appears to be recovering faster than initially thought.

Thanks to “back to work”-promotions and other marketing initiatives, Milestone Scientific wants to continue this development by meeting the needs of patients, dentists and other business partners. Despite total sales of $1.2 million this quarter being lower than the $1.9 million from the same period in 2019, the company sees the numbers turning out increasingly favorable. For example, the company reduced its net loss to $1.5 million ($ 0.02 per share) from the $2.8 million ($ 0.06 per share) it recorded in the same period a year ago.

Exploring CompuFlo Epidural System and CathCheck

With increasing demand for medical and dental products, the market can also be explored again for Milestone Scientific’s CompuFlo Epidural System and CathCheck (CompuWave ™) products. The company indicates that it will initially look for better and new sales efforts and collaboration opportunities. That the company has not taken a passive stance despite the pandemic became clear when a collective purchasing agreement was recently won with Premier. This is a highly recognized procurement organization with an impressive network including 4,100 American hospitals and 200,000 other providers. In doing so, Milestone Scientific is expanding its existing network beyond the major hospitals, medical schools and other medical opinion leaders it already works with.

CompuFlo Epidural System

The CompuFlo® Epidural Instrument offers objective detection of pressure changes to verify true loss of resistance and confirm the epidural space. What makes it unique is the Dynamic Pressure Sensing Technology® (DPS) Systems 1-4. Marked by 25% reduction in procedure time for labor and delivery epidurals and detects subtle pressure changes 4 times a second, making it extremely responsive to minor pressure changes. Because of this, clinicians can successfully perform epidural procedures with fewer attempts.

CathCheck (CompuWave™)

The CompuWave™ display shows pulsatile waveform found in the epidural space. The Epidural Catheter Verification System is fast and reads in seconds, not minutes. Through this it saves the anesthesia provider time, enabling them to make clinical decisions faster regarding ineffective epidural catheters and the next course of treatment. This increases the anesthesia provider’s daily effectiveness.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.